Hyperkalemia
Part of NephTimes
Advertisement
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
Potassium adsorbents lower serum potassium levels but their effects on mortality and rehospitalization rates were unclear.
Researchers sought to determine the palatability of SZC, patiromer, and S/CPS in patients with CKD and hyperkalemia.
Experts developed consensus statements for management of hyperkalemia in the Asia–Pacific region.
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes.
When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC.
Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias.
There are few data available on the adverse effect of hyperkalemia on progression of chronic kidney disease (CKD).
Patients with hyperkalemia treated with SCZ have a higher rate of continuation of RAAS inhibition.
Examining whether administration of patiromer would reduce the number of significant arrhythmia events.
Training an artificial intelligence algorithm that can detect hyperkalemia from the surface electrocardiogram.
There is an independent association between hyperkalemia and poor outcomes among individuals with chronic kidney disease.
Guideline recommendations call for maintenance of RAASi therapy using novel antihyperkalemia treatment.
At the 12-month follow-up, 100% of patients in the patiromer group remained on RAAS inhibitor therapy.
Concerns related to hyperkalemia are key in patients with CKD who are receiving other hyperkalemia-inducing agents.
Patients with chronic kidney disease (CKD) who develop hyperkalemia are at risk for serious adverse outcomes.
Participants were randomized to placebo or SZC 5 grams once daily on nondialysis days.
During an average follow-up of 3.9 years, 12.4% of patients (n=220,339) experienced at least one hyperkalemic episode.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.